ZURICH & NEWTON, Massachusetts--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers. The Massachusetts facility will initially focus on TrueDiscovery® data-independent acquisition (DIA) discovery proteomics services that offe ...